Increasing expression of serine protease matriptase in ovarian tumors: Tissue microarray analysis of immunostaining score with clinicopathological parameters

Modern Pathology

Volumn 19, Issue 3, 2006, Pages 447-452

  Jin, Jong Shiaw ^a   Hsieh, Dar Shih ^a   Loh, Shih Hurng ^b   Chen, Ann ^a   Yao, Chen Wen ^a   Yen, Chung Yang ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

Matriptase; Ovarian tumor; Serine protease; Serous adenocarcinoma

Indexed keywords

BIOLOGICAL MARKER; MATRIPTASE; SERINE PROTEINASE;

ADULT; ARTICLE; BRENNER TUMOR; CANCER STAGING; CLEAR CELL CARCINOMA; CORRELATION ANALYSIS; DYSGERMINOMA; FEMALE; FIBROMA; GRANULOSA CELL TUMOR; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY ADENOCARCINOMA; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TISSUE MICROARRAY; TRANSITIONAL CELL CARCINOMA; YOLK SAC TUMOR;

ADENOCARCINOMA, CLEAR CELL; ADULT; BRENNER TUMOR; CARCINOMA, ENDOMETRIOID; CARCINOMA, TRANSITIONAL CELL; CHILD; CYSTADENOCARCINOMA, MUCINOUS; CYSTADENOCARCINOMA, SEROUS; DYSGERMINOMA; ENDODERMAL SINUS TUMOR; FEMALE; FIBROMA; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OVARIAN NEOPLASMS; SERINE ENDOPEPTIDASES; TISSUE ARRAY ANALYSIS;

EID: 33244487758     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800495     Document Type: Article

References (28)

1. Piek JM, Kenemans P, Verheijen RH. Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its cause. Am J Obstet Gynecol 2004;191:718-732.
2. Brown E, Stewart M, Rye T, et al. Carcinosarcoma of the ovary: 19 years of prospective data from a single center. Cancer 2004;100:2148-2153.
3. Itamochi H, Kigawa J, Sugiyama T, et al. Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol 2002;100:281-287.
4. Shi YE, Torri J, Yieh L, et al. Identification and characterization of a novel matrix-degrading protease from hormone-dependent human breast cancer cells. Cancer Res 1993;53:1409-1415.
5. Lin CY, Wang JK, Torri J, et al. Characterization of a novel, membrane-bound, 80-kDa matrix-degrading protease from human breast cancer cells. Monoclonal antibody production, isolation, and localization. J Biol Chem 1997;272:9147-9152.
6. Lin CY, Anders J, Johnson M, et al. Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk. J Biol Chem 1999;274:18237-18242.
7. Lin CY, Anders J, Johnson M, et al. Molecular cloning of cDNA for matriptase, a matrix-degrading serine protease with trypsin-like activity. J Biol Chem 1999;274:18231-18236.
8. Zhang Y, Cai X, Schlegelberger B, et al. Assignment of human putative tumor suppressor genes ST13 (alias SNC6) and ST14 (alias SNC19) to human chromosome bands 22q13 and 11q24-q25 by in situ hybridization. Cytogenet Cell Genet 1998;83:56-57.
9. Takeuchi T, Shuman MA, Craik CS. Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc Natl Acad Sci USA 1999;96:11054-11061.
10. Tanimoto H, Underwood LJ, Wang Y, et al. Ovarian tumor cells express a transmembrane serine protease: a potential candidate for early diagnosis and therapeutic intervention. Tumour Biol 2001;22:104-114.
11. Oberst M, Anders J, Xie B, et al. Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo. Am J Pathol 2001;158:1301-1311.
12. Takeuchi T, Harris JL, Huang W, et al. Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem 2000;275:26333-26342.
13. Lee SL, Dickson RB, Lin CY. Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem 2000;275:36720-36725.
14. Fischer K, Lutz V, Wilhelm O, et al. Urokinase induces proliferation of human ovarian cancer cells: characterization of structural elements required for growth factor function. FEBS Lett 1998;438:101-105.
15. Corps AN, Sowter HM, Smith SK. Hepatocyte growth factor stimulates motility, chemotaxis and mitogenesis in ovarian carcinoma cells expressing high levels of c-met. Int J Cancer 1997;73:151-155.
16. Sowter HM, Corps AN, Smith SK. Hepatocyte growth factor (HGF) in ovarian epithelial tumour fluids stimulates the migration of ovarian carcinoma cells. Int J Cancer 1999;83:476-480.
17. Lam JS, Belldegrun AS, Figlin RA. Tissue array-based predictions of pathobiology, prognosis and response to treatment for renal cell carcinoma therapy. Clin Cancer Res 2004;10:6304s-6309s.
18. Pan CC, Chen PCH, Chiang H. An easy method for manual construction of high-density tissue arrays. Appl Immunohistochem Mol Morphol 2004;12:370-372.
19. Gabra H, Taylor L, Cohen BB, et al. Chromosome 11 allele imbalance and clinicopathological correlates in ovarian tumours. Br J Cancer 1995;72:367-375.
20. Gabra H, Watson JE, Taylor KJ, et al. Definition and refinement of a region of loss of heterozygosity at 11q23.3-q24.3 in epithelial ovarian cancer associated with poor prognosis. Cancer Res 1996;56:950-954.
21. Davis M, Hitchcock A, Foulkes WD, et al. Refinement of two chromosome 11q regions of loss of heterozygosity in ovarian cancer. Cancer Res 1996;56:741-744.
22. Connolly KC, Gabra H, Millwater CJ, et al. Identification of a region of frequent loss of heterozygosity at 11q24 in colorectal cancer. Cancer Res 1999;59:2806-2809.
23. Gudmundsson J, Barkardottir RB, Eiriksdottir G, et al. Loss of heterozygosity at chromosome 11 in breast cancer: association of prognostic factors with genetic alterations. Br J Cancer 1995;72:696-701.
24. Gentile M, Olsen K, Dufmats M, et al. Frequent allelic losses at 11q24.1-q25 in young women with breast cancer: association with poor survival. Br J Cancer 1999;80:843-849.
25. Hampton GM, Penny LA, Baergen KN, et al. Loss of heterozygosity in cervical carcinoma: subchromosomal localization of a putative tumor-suppressor gene to chromosome 11q22-q24. Proc Natl Acad Sci USA 1994;91:6953-6957.
26. Kim HL, Seligson D, Liu X, et al. Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol 2005;173:1496-1501.
27. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 2001;98:13790-13795.
28. Takahashi M, Rhodes DR, Furge KA, et al. Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc Natl Acad Sci USA 2001;98:9754-9759.